Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Holding APLS?
Track your performance easily

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

844 Followers
See the Price Targets and Ratings of:

APLS Analyst Ratings

Moderate Buy
19Ratings
13 Buy
6 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Apellis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$61.38
▲(126.33% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $61.38 with a high forecast of $92.00 and a low forecast of $25.00. The average price target represents a 126.33% change from the last price of $27.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","93":"$93","41.25":"$41.3","58.5":"$58.5","75.75":"$75.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,41.25,58.5,75.75,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.98,32.90461538461538,37.82923076923077,42.753846153846155,47.678461538461534,52.60307692307693,57.527692307692305,62.452307692307684,67.37692307692308,72.30153846153846,77.22615384615385,82.15076923076923,87.0753846153846,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.98,30.54923076923077,33.11846153846154,35.68769230769231,38.25692307692308,40.82615384615385,43.39538461538462,45.964615384615385,48.533846153846156,51.10307692307693,53.6723076923077,56.24153846153847,58.81076923076924,{"y":61.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.98,27.75076923076923,27.521538461538462,27.29230769230769,27.063076923076924,26.833846153846153,26.604615384615386,26.375384615384615,26.146153846153847,25.916923076923077,25.68769230769231,25.45846153846154,25.229230769230767,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.83,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.58,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.61,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.56,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.91,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.46,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.37,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.24,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.05,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.51,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$92.00Average Price Target$61.38Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo
$43
Hold
58.55%
Upside
Reiterated
10/27/24
Balanced Outlook on Apellis Pharmaceuticals: Promising Empaveli Data Amid Syfovre Growth Challenges
Robert W. Baird
$96$92
Buy
239.23%
Upside
Reiterated
09/23/24
Apellis price target lowered to $92 from $96 at BairdApellis price target lowered to $92 from $96 at Baird
Bank of America Securities
$61
Buy
124.93%
Upside
Reiterated
09/20/24
Maintaining Buy Rating on Apellis Pharmaceuticals Amid European Setback and US Market Focus
Wedbush
$41
Hold
51.18%
Upside
Reiterated
08/09/24
Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Oppenheimer
$65
Buy
139.68%
Upside
Reiterated
08/09/24
Oppenheimer Remains a Buy on Apellis Pharmaceuticals (APLS)

Best Analysts Covering Apellis Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy APLS and Sell After:
1 Month
xxx
Success Rate
19/30 ratings generated profit
63%
Average Return
+4.35%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.33% of your transactions generating a profit, with an average return of +4.35% per trade.
3 Months
xxx
Success Rate
15/24 ratings generated profit
63%
Average Return
+4.82%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +4.82% per trade.
1 Year
Success Rate
14/28 ratings generated profit
50%
Average Return
+7.60%
reiterated a buy rating 9 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.60% per trade.
2 Years
xxx
Success Rate
16/27 ratings generated profit
59%
Average Return
+34.04%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 59.26% of your transactions generating a profit, with an average return of +34.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
18
24
28
26
10
Buy
6
2
0
1
1
Hold
8
9
11
18
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
35
39
45
25
In the current month, APLS has received 11 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is $61.38.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.29 with a range of -$0.43 to -$0.17. The previous quarter’s EPS was -$0.30. APLS beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.84% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.
Next quarter’s earnings estimate for APLS is -$0.29 with a range of -$0.43 to -$0.17. The previous quarter’s EPS was -$0.30. APLS beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.84% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $200.00M with a range of $183.98M to $219.73M. The previous quarter’s sales results were $199.69M. APLS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.41% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.
Next quarter’s sales forecast for APLS is $200.00M with a range of $183.98M to $219.73M. The previous quarter’s sales results were $199.69M. APLS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.41% of the time in the same period. In the last calendar year APLS has Outperformed its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is $61.38.
    What is APLS’s upside potential, based on the analysts’ average price target?
    Apellis Pharmaceuticals Inc has 126.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is APLS a Buy, Sell or Hold?
          Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 13 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Apellis Pharmaceuticals Inc’s price target?
            The average price target for Apellis Pharmaceuticals Inc is $61.38. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $92.00 ,the lowest forecast is $25.00. The average price target represents 126.33% Increase from the current price of $27.12.
              What do analysts say about Apellis Pharmaceuticals Inc?
              Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of APLS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis